Spreng Capital Management’s Pfizer PFE Stock Holding History

Spreng Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,018	Closed	-$280K	–	87
2024 Q2	$280K	Buy	+10,018	New	+$276K	0.15%	71

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Spreng Capital Management's PFE Position: Q3 2024 in Review

Spreng Capital Management sold out of Pfizer (PFE) in Q3 2024, closing a stake of 10,018 shares — an estimated $280K sold.

Spreng Capital Management first reported a position in PFE in Q2 2024 and held it in 1 quarter. The position peaked at $280K in Q2 2024. 2,910 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

Spreng Capital Management reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
Spreng Capital Management sold 10,018 Pfizer shares in Q3 2024, an estimated $280K.
Spreng Capital Management first reported a position in Pfizer in Q2 2024 and held it in 1 quarter.
Spreng Capital Management's Pfizer position peaked at $280K in Q2 2024.
2,910 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Spreng Capital Management's 13F filing for Q3 2024, filed 17 Oct 2024.